Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 2

Status

Completed 4Terminated 3

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4

Conditions

Lymphoma, Non-Hodgkin 2Lymphoma 2Lymphoma, Follicular 1Hodgkin Disease 1

Interventions

Cyclophosphamide 1499Cisplatin 1435Paclitaxel 1340Radiotherapy 1310Carboplatin 1267Gemcitabine 1226Docetaxel 1133Bevacizumab 1070Fluorouracil 906Doxorubicin 805Dexamethasone 755Rituximab 744Capecitabine 735Oxaliplatin 709pembrolizumab 700Etoposide 679Irinotecan 639Filgrastim 624Cytarabine 587Nivolumab 586Leucovorin 583Vincristine 517Cetuximab 479Prednisone 478Bortezomib 474Trastuzumab 468Erlotinib Hydrochloride 467Surveys and Questionnaires 460Methotrexate 444Lenalidomide 436

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Completed × galiximab × Clear all
NCT00117975 2016-07-06

Rituximab and Galiximab in Treating Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Completed
62 enrolled
Lymphoid

Lymphoma, Lymphoma, Follicular

NCT00516217 2016-07-06

Galiximab in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Alliance for Clinical Trials in Oncology

Phase 2 Completed
30 enrolled 9 charts
Lymphoid

Hodgkin Disease, Lymphoma

NCT00048555 2013-09-16

Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
90 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

NCT00575068 2012-06-08

Safety and Efficacy of IDEC-114 in the Treatment of Non-Hodgkin's Lymphoma

Biogen

Phase 1/2 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon âš¡